Published Medical Literature

Osimertinib Cost-Effectiveness Falls Short of Payer Thresholds in First-Line EGFR+ NSCLC Use

Blood Transfusions During Nivolumab Linked to Worse Survival in Metastatic NSCLC

Bevacizumab Study Shows Reduced ILD Risk in Advanced NSCLC

Concurrent Chemoradiotherapy Outcomes in EGFR-Mutant Unresectable Stage III NSCLC

Real-World Study Supports Chemotherapy-Free Immunotherapy Combination in Advanced NSCLC

Predictors and Models for Stereotactic Radiosurgery Outcomes in NSCLC With Brain Metastases

NGS Demonstrates Higher Sensitivity Than PCR for Liquid Biopsy EGFR Mutation Detection in Treatment-Naïve NSCLC

Risk-Adapted Lung Cancer Screening Could Refine Care for Former Smokers

Multicenter RNA and Pathology Analysis Predicts Immunotherapy Outcomes in NSCLC

AI Model Predicts Rare Gene Mutations in Patients With Lung Adenocarcinoma

Preventing Skin Toxicities After Treatment With Nivolumab + Ipilimumab

Meta-analysis Suggests Benefit of ICIs Plus Chemotherapy for EGFR-Mutant, TKI-Resistant NSCLC

HER2 Expression Contributes to NSCLC Drug Resistance

Steroid Use Could Impact Checkpoint Inhibitor Efficacy in NSCLC

ALK+ NSCLC Presents as Rare Mediastinal Mass in Case Study

Enhancing Staging Accuracy for NSCLC Using Artificial Neural Networks

Zenocutuzumab Shows Antitumor Activity in NRG1 Fusion–Positive Cancers

Study Uncovers Alterations Triggered by Sotorasib Resistance in NSCLC

Germline Variants May Play Significant Role in Lung Cancer

Using Radiogenomic Signatures to Predict Survival in Patients With NSCLC and Brain Metastases

Comparing PD-1/PD-L1 Inhibitors in First-Line Setting of NSCLC

CSF Circulating Tumor Cell Assay for Diagnosing Leptomeningeal Disease in NSCLC

Early Immune Shifts May Predict Immunotherapy Success in NSCLC

Using STK11 and KEAP1 Mutations to Guide Clinical Management in NSCLC

Home-Based Exercise: An Economic Approach to Self-Care After Lung Cancer Surgery

Researchers Explore the Role of NCAPG in the Growth and Metastasis of NSCLC

Is Low-Dose CT Screening for Lung Cancer Also Effective at Detecting Coronary Artery Disease?

Eosinophil Counts: A Potential Biomarker for Predicting Immunotherapy Response in NSCLC?

Does Methylmalonic Acid Weaken Antitumor Immunity in Patients With Lung Cancer?

Unresectable, Primary NSCLC: Is SBRT of Benefit in Combination With Conventional Therapy?

Can Technologic Advance Identify Lung Cancer in Exhaled Breath?

Use of Liquid Biopsy to Predict Biomarkers for Immunotherapy for Advanced NSCLC

INCREASE STUDY: Immunotherapy Plus Chemoradiotherapy for Operable NSCLC

SABR for Early-Stage NSCLC: Dosimetric Variables That Matter Most

Study Identifies Potential Biomarker for Lung Squamous Cell Carcinoma

TROPION-Lung01: Dato-DXd vs Docetaxel in Advanced Lung Cancer

The Impact of Family Cancer History on Prognosis in Patients With NSCLC

Neoadjuvant Osimertinib Therapy for EGFR-Mutated NSCLC: Phase II Trial Update

Adding IDO1 Inhibitor to Immunotherapy in PD-L1–High Metastatic NSCLC

Solid Lung Nodules Found in Northern European Nonsmoking Cohort: Much to Be Learned

Does Where Patients Live Affect Their Chances of Surviving Lung Cancer?

Chemotherapy-Sparing Targeted Therapy Under Study in NSCLC After Osimertinib Resistance

Taletrectinib: A New TKI Under Study in the ROS1-Positive NSCLC Space

Age, Sex, Genomic Profiles Matter: Choosing Immunotherapies for Younger Patients With NSCLC

Analyzing Regional and Racial/Ethnic Differences in the Diagnosis of NSCLC

Predicting Response to Immunotherapy in NSCLC: AI-Powered PD-L1 Tumor Proportion Score Analyzer

Systemic Therapy for NSCLC: Prognostic Value of CT-Derived Body Composition Metrics

Who May Benefit From Telizotuzumab Vedotin in NSCLC? LUMINOSITY Trial Sheds Light

Intensity-Modulated Radiotherapy and Survival Outcomes in Locally Advanced NSCLC

SC vs IV Immune Checkpoint Inhibition in NSCLC: Is One Better Than the Other?

Can Comprehensive Genomic Profiling Influence Clinical Outcomes in Advanced NSCLC?

Using Smoking-Related Genes Predict Outcomes for Patients With NSCLC

Rare Case of Metastatic NSCLC Mimicking Metaplastic Breast Cancer

Wild-Type EGFR NSCLC: Folk Remedy Plus EGFR Tyrosine Kinase Inhibitors Under Study

Survival and Immune Checkpoint Inhibitor Efficacy in KRAS-Mutated NSCLC

Treatment-Related Hepatotoxicity in NSCLC: Are All KRAS G12C Inhibitors Created Equal?

Use of Atezolizumab Plus Cabozantinib Under Study When Other Treatments Fail in NSCLC

Impact of Timely Comprehensive Genomic Profiling for Patients With Advanced NSCLC

Selecting First-Line Treatment in Metastatic NSCLC: Plasma Proteomes Take Center Stage

NSCLC and Malignant Pleural Effusion: Immune Checkpoint Inhibitor Plus Chemotherapy

Novel Radiomics Model May Predict Cardiac Outcomes After Radiotherapy for Lung Cancer

Stereotactic Ablative Radiotherapy for Early-Stage NSCLC With Interstitial Lung Disease

New Research Supports HERC5 as a Potential Metastasis Suppressor Gene in NSCLC

Lung Cancer Screening Eligibility: Is Pack-Year Smoking History an Inadequate Measure?

Role of Sublobar Resection in Early-Stage NSCLC Treatment

Immunotherapy vs Chemoimmunotherapy: Which Is Best for Older Adults With NSCLC?

Outcomes With Immunotherapy for Metastatic NSCLC: An FDA Pooled Analysis

Early Research Sheds Light on EGFR Protein Interface, a Potential Target for Therapies in Lung Cancer

Early-Phase Study Shows Activity of Lazertinib in Advanced EGFR-Mutated NSCLC

Monitoring Chemotherapy Use for NSCLC: A View From New Zealand

Using an Antidepressant to Improve Appetite and Energy in Patients With NSCLC

Phase III INSPIRE Trial: Iruplinalkib vs Crizotinib in Metastatic ALK-Positive NSCLC

Is FLT3 Expression Linked to Survival in Lung Cancer? Polish Researchers Say Yes

Combination Therapy of Pevonedistat and Docetaxel Shows Promise for Relapsed NSCLC: Phase II Study Results

Locally Advanced NSCLC: Pembrolizumab Plus Risk-Adapted Radiotherapy Under Study

Single-Site Oligometastatic Lung Cancer: Is Resection of the Primary Tumor Beneficial?

Phase III Trial Supports Use of Toripalimab Plus Chemotherapy in Stage III NSCLC

BRAF V600E–Mutant Circulating Tumor Cells and Resistance to BRAF Inhibition in NSCLC

Immune Checkpoint Inhibitor Pneumonitis: Assessing Risk Factors in Patients With Lung Cancer

Chemotherapy Plus Osimertinib in EGFR-Mutated NSCLC: Update From FLAURA2

NDR2 Expression: A Useful Biomarker in Predicting Metastatic Risk in Patients With NSCLC?

CNS Activity in NSCLC: Osimertinib Plus Chemotherapy vs Osimertinib Monotherapy

Is There a Link Between Regional Influenza Activity and Mortality Among Patients With NSCLC?

CANOPY-1: Adding Monoclonal Antibody to Immunotherapy Regimen in NSCLC

Selpercatinib vs Chemotherapy for RET Fusion–Positive NSCLC: Phase III Findings

Phase III Trial Supports Use of Amivantamab in NSCLC With EGFR Exon 20 Insertions

Neoadjuvant Chemoimmunotherapy for Locally Advanced NSCLC: Who May Benefit?

Preoperative Splenic Area: Prognostic Biomarker for Early-Stage NSCLC?

Chemoradiotherapy and Immune Checkpoint Inhibitors in NSCLC: Insights on Impact of Induction

Dual Immunotherapy in the First-Line Setting of NSCLC: Ready for Prime Time?

Is Mass Spectrometry Useful in Detecting NSCLC Metastasis to Lymph Nodes?

2023 Lung Cancer Mortality Predictions in Europe

Lack of Success for Immunotherapy in Lung Cancer: Could the Reason Be Ineffective Priming of Cytotoxic T Lymphocytes?

Lorlatinib Continues to Outperform Crizotinib in 36-Month CROWN Follow-Up

RNA Modification and Tumor Immunity in Lung Cancer: Predicting Outcomes With Neoadjuvant Immunotherapy

Early Trial Results With Telisotuzumab Vedotin Plus Erlotinib in c-MET–Positive Lung Cancer

Can Predictive Models Determine 30-Day Mortality for Patients With Lung Cancer?

Streamlining the Process for Obtaining Next-Generation Sequencing Results in NSCLC

The Role of Postoperative Intensity-Modulated Radiation Therapy for Incompletely Resected NSCLC

How Oncogene-Driven Lung Cancer May Impact Pregnancy and Motherhood

5-Year Follow-up of KEYNOTE-042: Pembrolizumab Versus Chemotherapy in NSCLC

Can Artificial Intelligence Be Used to Predict the Presence of ALK Rearrangement in Lung Cancer?

PEARLS/KEYNOTE-091: Adjuvant Pembrolizumab in Completely Resected Stage IB–IIIA NSCLC

CT-Based Versus Minimal Follow-up for Patients With Resected NSCLC: Difference in Survival?

Are People Living With HIV at Increased Risk for Lung Cancer?

Can Immunotherapy After Chemoradiotherapy Improve Outcomes in Clinical Stage III Lung Cancer?

Early-Phase Trial Update on Use of Selpercatinib in RET Fusion–Positive NSCLC

Impact of Using Different Glomerular Filtration Rate Equations on Carboplatin Dosing in Lung Cancer

Clinical Validation of AI Models May Help Streamline Radiotherapy Planning in NSCLC

Research on the Biologic Mechanism Underlying Acquired Osimertinib Resistance in NSCLC

Modifiable Health System–Level Barriers Contribute to Lung Cancer Disparities

Can Artificial Intelligence Be Used to Develop a Decision Support Tool for Radiotherapy in NSCLC?

Phase III Trial of Aumolertinib Versus Gefitinib in EGFR-Mutated NSCLC

Trial Update on Tiragolumab Plus Atezolizumab as First-Line Treatment of NSCLC

CNS Metastasis From NSCLC: Discrepancies Between Public and Private Care in Brazil

Newer USPSTF Guidelines: Are More Black Patients Being Screened for Lung Cancer?

CheckMate 816: Nivolumab Plus Chemotherapy for Resectable NSCLC

Prolonged, Low-Level Exposure to Radon and Lung Cancer in Uranium Miners

Research Shows Anticancer Potential of Natural Compound Found in Barberry Plants

Novel Approach to Detecting Lung Cancer at the Cellular Level Under Study by Penn Medicine Researchers

Lung Cancer Risk: Study Identifies Potential Mechanism in Patients With a Smoking History

Hypofractionated Proton Therapy Plus Chemotherapy for Locally Advanced Lung Cancer

NOP56 and mTOR Cooperation Mechanism in KRAS-Mutant Lung Cancer

Researchers Explore Novel Process for Predicting Lung Cancer Recurrence

Radiation Therapy for NSCLC: Are There Racial Differences in Treatments and Side Effects?

PPDPF Overexpression: An Avenue for Further Research in Lung Cancer?

Treatment After Osimertinib Discontinuation in Real-World Setting of Metastatic NSCLC

Common Genes Associated With Overall Survival in NSCLC

Trends in the Cost of Agents Used to Treat Metastatic NSCLC

Early Research May Support Targeting PGM3 in Lung Cancer With Concurrent Mutations

How Effective Is Cell-Free ctDNA Profiling in Managing Advanced Lung Cancer?

Understanding Resistance to KRAS Inhibitors in Patients With NSCLC

Can Driver Genetic Alterations Predict Survival in Advanced Lung Adenocarcinoma?

COVID-19 and NSCLC: How Resilient Are Patients With Advanced Lung Cancer?

Adjuvant Atezolizumab Versus Best Supportive Care in Resected Early-Stage NSCLC: IMpower010 Results

Use of Nintedanib/Docetaxel in Advanced Nonsquamous Lung Cancer: Phase III Trial Results

Does Bias Affect Overall Survival Reporting in ALK-Positive NSCLC Treated With Alectinib Versus Ceritinib?

Update From ALTER-L004: First-Line Anlotinib Plus Icotinib in EGFR-Mutated NSCLC

IMPACT Trial of Adjuvant Gefitinib in EGFR-Mutated NSCLC

Case Study in Advanced Lung Cancer: EML4-NTRK Gene Fusion and ALK Inhibitor Resistance

Is Neoadjuvant PD-1 Inhibition Plus Chemotherapy of Benefit in Locally Advanced NSCLC?

Phase II Trial Shows Activity of Poziotinib in HER2 Exon 20–Mutant NSCLC

Final Overall Survival Results From APOLLO of Aumolertinib in Advanced NSCLC

Phase II Study of Anlotinib Plus Doxetaxel for Relapsed NSCLC

Sintilimab Plus Pemetrexed and Platinum for NSCLC: Updated ORIENT-11 Study Results

Locally Advanced NSCLC: Outcomes With Metformin Plus Chemoradiotherapy

KEYNOTE-010 Update: Long-Term Benefits Continue With Pembrolizumab in NSCLC

Is Proton Beam Therapy Effective in Locally Controlling Early-Stage NSCLC?

Phase III ACTIVE Trial: Apatinib Plus Gefitinib as First-Line Treatment in NSCLC

How Does Stereotactic Ablative Radiotherapy Measure Up Against Surgery in Stage I NSCLC?

Is T-DXd Active Against HER2-Mutant NSCLC?

Docetaxel Plus Intercalated Erlotinib Versus Docetaxel Alone in Nonsquamous Lung Cancer

Can Neuronal Autoantibodies Influence Cognitive Impairment in Patients With Lung Cancer?

Early Detection of Primary Lung Cancer Using Low-Dose CT Screening and Risk of Brain Metastases

Stage III NSCLC: Diversity of Treatment Practices and Outcomes in Real-World Setting

Can the Combination of CDK4 and MEK Inhibitors Reduce Resistance to Lung Cancer Therapy?

RATIONALE 304: Tislelizumab Plus Chemotherapy for Advanced Nonsquamous Lung Cancer

Can a Deep Learning Algorithm Predict the Risk of Pulmonary Nodules Becoming Cancerous?

Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel in Advanced Lung Cancer

Effective Combination Therapy for COVID-19 Featured in a Patient With Lung Cancer

Proof-of-Concept Trial of Chemotherapy Plus Immune Checkpoint Inhibitor in Unresectable NSCLC

CodeBreaK100: Sotorasib for KRAS-Mutated Lung Cancer

Adding Stereotactic Body Radiotherapy to Immunotherapy for Early-Stage NSCLC

Nab-paclitaxel Monotherapy in EGFR-Mutated Advanced Lung Cancer

Medicare-Insured Patients With Advanced Lung Cancer: Does First-Line Immunotherapy Improve Survival?

Rare Case of STRN-ALK Rearrangement in Lung Cancer

Comparing TKIs as First-Line Treatment in Japanese Patients With NSCLC

Novel Method to Predict Cardiovascular Mortality Risk at Lung Cancer Screening

ORIENT-12 Trial: Sintilimab Plus Standard Chemotherapy for Metastatic Lung Cancer

Lung Cancer Risk Prediction Models and Racial Disparities

Inhibition of ROS1 in NSCLC: Updated Integrated Analysis of Three Clinical Trials

Making Progress in Targeting KRAS in Non–Small Cell Lung Cancer

Neoadjuvant Combination Immunotherapy for Operable Lung Cancer: NEOSTAR Trial Update

Immune Checkpoint Inhibitors and Cardiac Toxicity in Patients With Lung Cancer

NSCLC With Brain Metastases: Concurrent Chemotherapy and Whole-Brain Radiotherapy

Can Osimertinib Plus Bevacizumab Improve Outcomes in Advanced EGFR T790M–Mutated Lung Cancer?

EGFR-TKI Therapy for Lung Cancer: Can Machine Learning Model Identify Patients Unlikely to Benefit?

CheckMate 9LA: First-Line Immunotherapy Plus Chemotherapy in NSCLC

Lung Cancer Screening Amid the COVID-19 Pandemic

Radiotherapy Dose Exposure Thresholds and Adverse Cardiac Events in Patients With NSCLC

Smoking Behavior in Patients With Early-Stage NSCLC Enrolled in Clinical Trial

Examining Treatment Resistance in RET Fusion–Positive NSCLC

Can Supertype B44 HLA Antigen Shape Tumor Response in NSCLC?

Neoadjuvant Chemoimmunotherapy for Resectable Stage IIIA NSCLC

Study Finds Ethnic Association With Oncogenic Mutations for Patients With Lung Carcinoma

Can Lung Microbiome Enrichment Improve Outcomes for Patients With Lung Cancer?

Combining Novel Monoclonal Antibody With Radiotherapy for NSCLC

Atezolizumab Plus VEGF Inhibition in Stage IV Lung Cancer

AURA3 Overall Survival Analysis: Osimertinib Versus Chemotherapy for Advanced Lung Cancer

Novel PD-1 Antibody Shows Activity in Advanced Lung Cancer

Osimertinib in Treatment of EGFR-Mutated NSCLC: From the ADAURA Trial

Comparing Risk Prediction Models in Lung Cancer Screening: Focus on Black Smokers

Does a History of Smoking Influence the Molecular Diversity of Lung Tumors?

Study Explores Adoptive Cell Therapy for Refractory NSCLC

Update on Population-Level Mortality Rates in Lung Cancer

Case Report: Lung Cancer and SARS-CoV-2–Related Microthrombi

Online Tool Under Study to Improve Adherence to Guideline-Concordant Care in NSCLC

Combination Immunochemotherapy in Locally Advanced or Metastatic NSCLC

Lung Cancer and COVID-19: Effect on Treatment Scheduling

Palbociclib Monotherapy for Advanced NSCLC With CDKN2A Alterations

HER2-Mutant Advanced Lung Cancer: Pyrotinib After Chemotherapy

Selecting Initial Therapy in NSCLC: First Step Is Histology

Palbociclib Plus Osimertinib Under Study in Tyrosine Kinase Inhibitor–Resistant NSCLC

NSCLC and Bone Metastases: Loading Doses of Ibandronate for Bone Pain

Erlotinib in the Treatment of Lung Cancer With Leptomeningeal Metastases

Durvalumab in Advanced Lung Cancer: Final Overall Survival Data From ATLANTIC Trial

Stereotactic Body Radiotherapy Plus Adjuvant Chemotherapy for Older Patients With Lung Cancer

ALEX Study Update on Alectinib for ALK-Positive Non–Small Cell Lung Cancer

Long-Term Outcomes With Pembrolizumab for NSCLC and Brain Metastases

Advanced NSCLC: Tepotinib for MET Exon 14 Skipping Mutation

First-line Osimertinib and Bevacizumab Treatment in Metastatic EGFR-Mutant Lung Cancer

Third-Generation EGFR Tyrosine Kinase Inhibitor in Lung Cancer

Pneumonitis in Patients Treated With Chemotherapy or Immunotherapy

COVID-19 and Lung Cancer: Focus on ALK/ROS1 Inhibitors

Safety of Combination Triplet for Lung Cancer in KEYNOTE-189

Tumor-Infiltrating Lymphocytes in Metastatic Lung Cancer

EML4-ALK Mutations and Lorlatinib Treatment in Lung Cancer

Does Patients' Knowledge of Lung Cancer Diagnosis Improve Survival Outcomes?

Beyond Skin Cancer: BRAF Inhibition in Solid Tumors Including Lung Cancer

Can AXL Inhibitor Overcome Treatment Resistance in EGFR-Mutant Lung Cancer?

First-Line Treatment Outcomes in Metastatic NSCLC: Real-World Patterns

Locally Advanced NSCLC and COVID-19: Alternative Treatment Strategies

Locoregional Recurrent Versus de Novo Locally Advanced NSCLC: Patient Outcomes

Chemoradiotherapy Plus Pembrolizumab for Stage III Lung Cancer

Novel Algorithm for Selecting Patients for Lung Cancer Treatment: EGFR Mutations Are Key

Durvalumab in Unresectable NSCLC: Are Outcomes Affected by PD-L1 Expression?

Risk of ICU Admission in Patients With Lung Cancer

Pembrolizumab Plus Chemotherapy for Metastatic Lung Cancer: Quality-of-Life Outcomes

Early-Phase Trial Studies Capmatinib in Advanced NSCLC

Smoking Cessation Interventions During Lung Cancer Screening

Adding Pemetrexed to Bevacizumab in Advanced Nonsquamous Lung Cancer

Tumor Mutation Burden in Metastatic NSCLC: Predictive of Response to Pembrolizumab?

Antibiotics and Proton Pump Inhibitors May Affect Outcomes in Patients Treated for Metastatic Lung Cancer

Osimertinib in Patients With Lung Cancer Who Have Uncommon EGFR Mutations

Heat Shock Protein 90 Inhibitor in Lung Cancer: GALAXY Clinical Trials

Robotic Bronchoscopy for Pulmonary Biopsy

Does Adding Cetuximab to Radiotherapy Improve Survival in Unresectable Lung Cancer?

Mortality Benefits of CT Screening for Lung Cancer in High-Risk Persons

Gefitinib Alone and in Combination for Untreated EGFR-Mutated Lung Cancer

Are Patients Older Than 90 Candidates for Lung Cancer Treatment?

Pemetrexed and Carboplatin Plus TKI in Advanced EGFR-Mutant Lung Cancer

Early-Phase Studies of Entrectinib for the Treatment of NTRK Fusion–Positive Solid Tumors

Role of Bevacizumab in Patients With Advanced NSCLC With Liver Metastases

Predicting Toxicity in Patients With Lung Cancer Treated With Pemetrexed

Can Consumption of Dietary Fiber and Yogurt Lower the Risk of Lung Cancer?

First-in-Human Study of Lazertinib in EGFR-Mutated Advanced Lung Cancer

Can BCG Vaccination During Childhood Reduce the Risk of Subsequent Lung Cancer?

First-in-Class Pegilodecakin Plus Immunotherapy Under Study in Lung Cancer

Bevacizumab Plus Erlotinib or Erlotinib Alone in EGFR-Mutated Lung Cancer

How Accurate Are Chest X-rays in Detecting Lung Cancer?

ASCEND-7 Trial: Use of Ceritinib for ALK-Positive Lung Cancer

Researchers Study Possible Link Between E-Cigarette Smoke and Lung Cancer

Researchers Study Possible Link Between E-Cigarette Smoke and Lung Cancer

Long-Term Survival With Nivolumab in Advanced Lung Cancer

Extended Follow-up From the National Lung Screening Trial

Insurance and Mortality in Lung and Other Cancers

Early Palliative Care and Survival in Patients With Advanced Lung Cancer

Oral Nelfinavir With Chemoradiotherapy for Locally Advanced Lung Cancer

Does Corticosteroid Use Affect Outcomes With Checkpoint Inhibitors in NSCLC?

Risk of HBV Reactivation During Therapy for Non–Small Cell Lung Cancer

Is Pembrolizumab of Benefit in Oligometastatic Lung Cancer After Local Ablative Therapy?

Nivolumab for Advanced Lung Cancer: 5-Year Survival

IMpower130 Supports Atezolizumab Inclusion in Stage IV Lung Cancer Therapy

Is Biennial Lung Cancer Screening Safe and Effective?

How an Intervention Trial Addressed Racial Disparities in Treatment of Early-Stage Cancers

Does Stereotactic Body Radiotherapy Enhance the Effect of Immunotherapy for Lung Cancer?

Is Lung Cancer Screening Effective in the Community Setting?

Statin Use After Radiotherapy for Survivors of Thoracic Cancer

Utility of Educational Video Regarding Lung Cancer Screening

Cardiovascular Toxicity in Patients Treated With Radiotherapy for Lung Cancer

Adding Erlotinib to Bevacizumab in EGFR-Positive Lung Cancer

Adding Bevacizumab to Carboplatin/Pemetrexed in Nonsquamous NSCLC

Innovative Drug Delivery System in Lung Cancer: Combining Quantum Dots and TKIs

Lifetime Incidence of Brain Metastasis in Elderly Survivors of Lung Cancer

Combining Plasma and Tissue Genotyping in EGFR-Mutant Lung Cancer

Five-Fraction Stereotactic Body Radiation Therapy for Centrally Located Lung Tumors

Correlation Between Blood and Tumor T-Cell Cytotoxicity May Predict Treatment Effectiveness

Chronic Opioid Use in Older Lung Cancer Survivors

Transformation of NSCLC to Small Cell Lung Cancer

Combination Therapy May Be Key to Treating KRAS-Mutant NSCLC

Immunotherapy for Advanced Lung Cancer: Is Tumor Mutational Burden Linked to Response?

Stereotactic Ablative Radiotherapy for Inoperable Early-Stage Lung Cancer

Does Prophylactic Cranial Irradiation Extend Survival in Locally Advanced Lung Cancer?

Shared Decision-Making in Lung Cancer Treatment: Patient Priorities and Preferences

Can MET Copy Number Predict TKI Resistance in EGFR -Mutant NSCLC?

Immunotherapy for Patients With NSCLC and HIV Infection

New Combination Therapy for NSCLC Tested in Phase II Trial

Tisotumab Vedotin Exhibits Antitumor Activity in NSCLC, Among Other Cancers

Pembrolizumab Versus Platinum-Based Chemotherapy in Advanced NSCLC

System-Based Intervention Designed to Reduce Racial Disparities in Lung Cancer Treatment

Does Afatinib Improve Outcomes in HER2-Mutant Lung Cancer?

Use of Lorlatinib in ALK-Positive NSCLC

Tumor Mutation Burden as Prognostic Biomarker in Non–Small Cell Lung Cancer

16-Year Trends in Aggressive End-of-Life Care in Patients With Lung Cancer

Variables Influencing Overall Survival in ALK-Positive NSCLC

SELECT Trial: Adjuvant Erlotinib in Resected EGFR-Mutant NSCLC

Pembrolizumab Plus Chemotherapy in Metastatic Squamous NSCLC

Does Pulmonary Fibrosis Increase the Risk of Pneumonitis Related to Anti–PD-1 Treatment?

Combination Epacadostat and Pembrolizumab in NSCLC

Could Thermal Ablation Rival Stereotactic Radiation Therapy in Early-Stage Lung Cancer?

Examining Emotional Effects on Long-Term Lung Cancer Survivors

JAVELIN Lung 200: Avelumab Versus Docetaxel in Advanced Lung Cancer

Surgery Type for Lung Cancer May Influence Later Opioid Use

Epigenetic Alterations and Tumor Mutational Burden in NSCLC

Does Early CT Screening for Lung Cancer Reduce Mortality?

Do Brain Metastases Affect Outcomes With Immunotherapy?

Can Salvage Treatment Improve Survival in Early-Stage Lung Cancer?

Impact of Neoadjuvant Erlotinib on Radical Resection Rate in Patients With NSCLC

Acquired Osimertinib Resistance in EGFR-Positive NSCLC

Does Baseline Steroid Use Impact Efficacy of Immunotherapy in Patients With NSCLC?

New Test May Help Risk Stratify Patients With NSCLC for Treatment

Osimertinib Treatment in T790M-Positive NSCLC With CNS Metastases

Should Cisplatin Accompany First-Line NSCLC Treatment in Elderly Patients?

Review Features Clinical Challenges of Personalized Treatment in NSCLC

ERBB Mutation as Predictive Biomarker for Afatinib Treatment in Lung Cancer

Is Ado-Trastuzumab Emtansine Active in HER2-Mutant Lung Cancer?

Addition of Biomarker Panel to Lung Cancer Screening: Can It Improve Detection of Disease?

Retrospective Analysis of Brain Metastases in Patients With Stage IV NSCLC

Does Prior Antibiotic Use Affect Treatment Outcomes in Lung Cancer?

Brigatinib Active in Patients With ALK-Positive Lung Cancer

Overall Survival Benefit of Crizotinib in Patients With ALK-Positive NSCLC

How Accurate Are Lung Cancer Risk Models for Selecting Ever-Smokers for Screening?

Screening for Intracranial Disease in Patients With Lung Cancer Versus Breast Cancer

ASTRO Updates Guideline for Palliative Radiation Therapy for Lung Cancer

Immune Stimulant in Combination With Nivolumab for Metastatic Lung Cancer

Efficacy of Immunotherapy for Lung Cancer: Does Gender Matter?

Risk of Brain Metastases in Patients With NSCLC

Updated ASTRO Guideline Focuses on Palliative Radiotherapy for Lung Cancer

Review Offers 2018 Roadmap for Treating Advanced Non–Small Cell Lung Cancer

Geographic Disparity Observed in Lung Cancer Deaths in Women

Hypoxia as Therapeutic Target in Non–Small Cell Lung Cancer

Durvalumab in Heavily Pretreated Patients With Advanced Lung Cancer

Predictor of Response Rates to Anti–PD-1 Therapies Across Cancer Types

Long-Term Survival With Nivolumab in Pretreated Patients With Advanced Lung Cancer

Update on Genomic Testing for Patients With Lung Cancer

Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer

Risk of Second Primary Lung Cancer After Treatment of Primary Lung Tumor

ASCO Endorses Molecular Testing Guideline Update for TKI Treatment in Lung Cancer

Update on Treatment of Oligometastatic Lung Cancer

Targeted Next-Generation Sequencing for Predicting Treatment Response in Lung Cancer

Targeted Radiation vs. Surgery for Early-Stage Lung Cancer

Osimertinib in Treating CNS Metastases From Lung Cancer

Combination Therapy for Previously Untreated Advanced Lung Cancer

Chemoradiation Versus Radiation Alone in Elderly Patients With Lung Cancer

Effect of Pembrolizumab on Quality of Life for Patients With Advanced Lung Cancer

Radiosurgery vs. Whole-Brain Radiation for Brain Metastases in Patients With Lung Cancer

Should Bevacizumab Accompany Adjuvant Chemotherapy in Early-Stage NSCLC?

Osimertinib as First-line Treatment of EGFR-Mutant Advanced NSCLC

Long-Term Outcomes With Nivolumab vs. Docetaxel in Advanced Lung Cancer

Safety of Checkpoint Inhibitors Plus Radiotherapy for Metastatic Lung Cancer

Dacomitinib vs. Gefitinib in First-Line Treatment of EGFR Mutation–Positive NSCLC

Gefitinib Plus Chemotherapy in the IMPRESS Trial: Final Overall Survival

Does Adding Motesanib to Paclitaxel/Carboplatin Improve Outcomes in East Asian Patients With Lung Cancer?

Icotinib vs. Chemotherapy in EGFR-Positive Lung Adenocarcinoma

Dabrafenib and Trametinib in BRAF V600E–Mutant Metastatic NSCLC

Hair Repigmentation and Response to Immunotherapy for NSCLC

Consolidative Radiotherapy Prior to Chemotherapy for Limited Metastatic NSCLC

Are Immune-Related Adverse Events With Nivolumab Linked to Efficacy in NSCLC?

First-Line Treatment With Osimertinib in EGFR Mutation–Positive Advanced NSCLC

Pathologic Nodal Staging Quality and Survival Differences in Non–Small Cell Lung Cancer

Immunotherapy After Chemoradiotherapy for Stage III Lung Cancer

Adding First-Line Ipilimumab to Chemotherapy for Squamous NSCLC

Fat Intake and Risk of Lung Cancer

COPD Treatment Initiative for Patients With Lung Cancer

Frequency of Lung Cancer in Never-Smokers in the UK

Surfactant Protein D and Clinical Outcomes in Lung Cancer

Use of Supplemental Vitamin B and Risk of Lung Cancer

Comparing Chemotherapy Regimens With Gemcitabine and Cisplatin in Advanced NSCLC

Combination Therapy With Apatinib in Resistant NSCLC

Updated Molecular Analyses in NSCLC Patients Treated With Erlotinib

Driver Mutations and Therapy Selection for Lung Adenocarcinoma

Concurrent Chemotherapy and Proton Therapy in Advanced Lung Cancer

Robot-Assisted Thoracic Surgery for Lung Lobectomy in NSCLC

Brigatinib in Crizotinib-Refractory ALK-Positive Non–Small Cell Lung Cancer

Nivolumab in the First-Line Treatment of Advanced or Recurrent Lung Cancer

Atezolizumab in PD-L1–Selected Advanced Non–Small Cell Lung Cancer

Cost Analysis of Personalized vs Fixed Dosing of Pembrolizumab

Alectinib and CNS Response in Resistant ALK-Positive Disease

Alectinib vs Crizotinib in ALK-Positive NSCLC

Potential Biomarker in Lung Squamous Cell Carcinoma

Early-Phase Trial of Vaccine in NSCLC

Brigatinib in Patients With Crizotinib-Refractory ALK-Positive NSCLC

Local Ablative Therapy for Oligometastatic Lung Cancer

Addition of Selumetinib to Docetaxel in KRAS-Mutant Lung Cancer

Chromosome Instability: Potential Prognostic Predictor in Lung Cancer

Multikinase Inhibitors in RET-Rearranged NSCLC

A Population-Based Comparative Effectiveness Study of Chemoradiation Regimens and Sequences in Stage III NSCLC

Osimertinib or Platinum/Pemetrexed in EGFR T790M–Positive Lung Cancer

Impact of Reflex EGFR/ALK Testing on Time to Treatment of Patients With Advanced Nonsquamous NSCLC

Proportion of Never-Smoker NSCLC Patients at Three Diverse Institutions

Atezolizumab vs Docetaxel in Patients With Previously Treated NSCLC (OAK): A Phase 3, Open-Label, Multicentre Randomised Controlled Trial

Management Strategies for Adverse Events Associated With EGFR TKIs in NSCLC

Treatment of Stage IIIA NSCLC

Can Pan-TRK Immunohistochemistry Identify NTRK Fusions in Lung Cancer?

Larotrectinib for Advanced Lung Cancer With Novel NCOR2-NTRK1 Fusion: Case Study